Composition for inhibiting activity of cyclooxygenase-2 and application thereof

Abstract

The invention relates to the technical field of compositions, in particular to a composition for inhibiting the activity of cyclooxygenase-2 and application of the composition. The composition is prepared from the following components in parts by weight: 20 to 50 parts of astaxanthin, 3 to 10 parts of radix astragali seu hedysari extract, 3 to 10 parts of radix codonopsis extract, 1 to 10 parts of deer glue peptide and 1 to 10 parts of albumin peptide. The astaxanthin is combined with the astragalus extract, the codonopsis pilosula extract, the deer glue peptide and the albumin peptide to obtain the composition capable of remarkably inhibiting the activity of the cyclooxygenase-2, and the composition has a wider application range and can be used for preparing a preparation for inhibiting the activity of the cyclooxygenase-2.

Description

Technical Field

[0001] The present invention relates to the technical field of compositions, in particular to a composition for inhibiting cyclooxygenase-2 activity and application thereof. Background Art

[0002] Prostaglandin peroxide synthase, also known as cyclooxygenase or cyclooxygenase (COX), is a rate-limiting enzyme that plays an important role in the synthesis of prostaglandins, catalyzing the conversion of arachidonic acid into prostaglandins, etc. There are two main subtypes of cyclooxygenase, cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2). The two have the same relative molecular mass, but there are differences in the amino acid sequence, resulting in different secondary and tertiary structures. Therefore, the active agent substrate selectivity of these two enzymes is also different. Among them, COX-2 is an inducible gene, that is, it is generally not expressed in the body under normal circumstances, and is only expressed when induced or stimulated, such as local synthesis and overexpression under the action of cytokines, growth factors, inflammatory mediators, tumorigenic factors, etc.

[0003] Modern pharmacological studies have shown that COX-2 is associated with many diseases, for example, (1) related to inflammation: prostaglandins produced by COX-2 play a major role in inflammatory reactions; COX-2 expression increases in a large number of inflammatory models. (2) related to neurodegenerative diseases: a large number of studies have shown that inflammation occurs during the occurrence and development of neurodegenerative diseases; COX-2 expression increases in the forebrain of AD patients, and beta-amyloid protein stimulation can induce the expression of COX-2 in neuronal cells SH-SY5Y. (3) related to atherosclerosis: Baker et al. showed that monocytes, macrophages, endothelial cells, and smooth muscle cells in human arteriosclerotic lesions all express COX-2, indicating that COX-2 may have the function of promoting the occurrence of inflammation in the process of atherosclerosis formation. (4) related to cancer: cancer genes, growth factors, cytokines, chemotherapy, and tumor stimulating factors can stimulate COX-2 transcription through protein kinase C and Ras-mediated signaling pathways; COX-2 is overexpressed in tumor tissues, and COX-2 is also associated with the occurrence of cancer.

[0004] At present, the test articles reported for the regulation of COX-2 are mainly concentrated on Cistanche deserticola polysaccharide, bupleurosaponin, chalcone of glycosides, deangic acid tea water extract, tetrandrine, water extract of pteris viridis, sea bass immune peptide, sesquiterpene dimer compound in Hubei Jinsulan, chlorogenic acid, Antarctic krill oil, ginsenoside, cryptotanshinone, total phenolic acid of Saussurea involucrata, alcohol extract of Rhizoma Cibotii, inula lactone, water extract of chrysanthemum indica, sodium houttuynia, alcohol extract of Ginger, etc. In order to enrich the types of substances used to regulate COX-2, the present invention is specially proposed. Summary of the invention

[0005] One object of the present invention is to provide a composition that can significantly inhibit the activity of cyclooxygenase-2.

[0006] Another object of the present invention is to provide a use of the above composition in preparing a preparation for inhibiting cyclooxygenase-2 activity.

[0007] In order to achieve the above-mentioned object of the present invention, the present invention provides a composition on the one hand, comprising the following components in parts by weight:

[0008] 20-50 parts of astaxanthin, 3-10 parts of astragalus extract, 3-10 parts of codonopsis extract, 1-10 parts of deer glue peptide and 1-10 parts of albumin peptide.

[0009] In a specific embodiment of the present invention, the composition comprises the following components by weight: 35-45 parts of astaxanthin, 5-7 parts of astragalus extract, 5-7 parts of codonopsis extract, 4-6 parts of deer glue peptide and 4-6 parts of albumin peptide.

[0010] In a specific embodiment of the present invention, the astaxanthin is derived from Haematococcus pluvialis. Further, the astaxanthin is astaxanthin microcapsule powder.

[0011] In a specific embodiment of the present invention, the total nitrogen of the deer glue peptide is ≥15wt%.

[0012] In a specific embodiment of the present invention, the albumin peptide has a protein content of ≥75wt% and an oligopeptide content of ≥60wt%.

[0013] In a specific embodiment of the present invention, the astragalus extract is a water extract of astragalus, and the codonopsis extract is a water extract of codonopsis.

[0014] In a specific embodiment of the present invention, in the composition, the protein content is ≥1.82wt%, the fat content is ≥0.2wt%, and the carbohydrate content is ≥24.5wt%.

[0015] In a specific embodiment of the present invention, the composition comprises at least one of powder, granules, tablets, capsules and oral liquid.

[0016] In a specific embodiment of the present invention, the composition further comprises an auxiliary material. Further, the auxiliary material comprises at least one of sorbitol, magnesium stearate and silicon dioxide.

[0017] Another aspect of the present invention provides a method for preparing any one of the above-mentioned compositions, comprising the following steps: mixing the components in proportion.

[0018] Another aspect of the present invention provides use of any one of the above-mentioned compositions in the preparation of a preparation for inhibiting cyclooxygenase-2 activity.

[0019] In a specific embodiment of the present invention, the preparation comprises at least one of food, health care product and medicine.

[0020] Compared with the prior art, the present invention has the following beneficial effects:

[0021] (1) The present invention uses astaxanthin in combination with astragalus extract, codonopsis extract, deer glue peptide and albumin peptide to obtain a composition that can significantly inhibit the activity of cyclooxygenase-2;

[0022] (2) The composition of the present invention contains polypeptide, astaxanthin and Chinese herbal medicine extract. The Chinese herbal medicine extract is a substance listed in the catalog of medicine and food homology. Astaxanthin is managed as a new resource food raw material. The composition can be used as food according to regulations and has a wider range of applications. It can be used to prepare preparations that inhibit cyclooxygenase-2 activity. BRIEF DESCRIPTION OF THE DRAWINGS

[0023] In order to more clearly illustrate the specific implementation methods of the present invention or the technical solutions in the prior art, the drawings required for use in the specific implementation methods or the description of the prior art will be briefly introduced below. Obviously, the drawings described below are some implementation methods of the present invention. For ordinary technicians in this field, other drawings can be obtained based on these drawings without paying creative work.

[0024] Figure 1 Effects of the composition prepared in Example 1 of the present invention and Comparative Examples 1 and 2 on the proliferation of RAW264.7 cells;

[0025] Figure 2 The effects of the composition prepared in Example 1 of the present invention and Comparative Examples 1 and 2 on IL-6 levels; wherein, **: comparison between the model group and the blank group; ##: comparison between the dose group and the model group;

[0026] Figure 3 The effects of the composition prepared in Example 1 of the present invention and Comparative Examples 1 and 2 on COX-2 levels; wherein, **: comparison between the model group and the blank group; #, ##: comparison between the dosage group and the model group. DETAILED DESCRIPTION

[0027] The technical scheme of the present invention will be clearly and completely described below in conjunction with the accompanying drawings and specific embodiments, but it will be understood by those skilled in the art that the following described embodiments are part of embodiments of the present invention, rather than all embodiments, and are only used to illustrate the present invention, and should not be considered as limiting the scope of the present invention. Based on the embodiments in the present invention, all other embodiments obtained by those of ordinary skill in the art without making creative work are within the scope of protection of the present invention. If specific conditions are not specified in the embodiments, they are carried out according to normal conditions or conditions recommended by the manufacturer. If the manufacturer is not specified in the reagents or instruments used, they are all conventional products that can be purchased commercially.

[0028] At present, the research on the physiological function of astaxanthin mainly focuses on anti-oxidation, anti-tumor, treatment of diabetes, improving the body's immune function, and preventing the occurrence of cardiovascular and cerebrovascular diseases. The effect of astaxanthin on COX-2 activity is relatively rare. Based on this, the present invention provides a composition, including the following components by weight: 20-50 parts of astaxanthin, 3-10 parts of astragalus extract, 3-10 parts of codonopsis extract, 1-10 parts of deer glue peptide and 1-10 parts of albumin peptide.

[0029] For example, in different embodiments, the amounts of the components in the composition can be as follows, by weight:

[0030] The amount of astaxanthin can be 20 parts, 25 parts, 30 parts, 35 parts, 40 parts, 45 parts, 50 parts or a range consisting of any two of them;

[0031] The amount of the astragalus extract can be 3 parts, 4 parts, 5 parts, 6 parts, 8 parts, 10 parts or a range consisting of any two of them;

[0032] The dosage of Codonopsis pilosula extract can be 3 parts, 4 parts, 5 parts, 6 parts, 8 parts, 10 parts or a range consisting of any two parts thereof;

[0033] The dosage of deer glue peptide can be 1 part, 2 parts, 4 parts, 5 parts, 6 parts, 8 parts, 10 parts or a range consisting of any two of them;

[0034] The amount of albumin peptide can be 1 part, 2 parts, 4 parts, 5 parts, 6 parts, 8 parts, 10 parts or a range consisting of any two parts thereof.

[0035] Among them, Astragalus is a perennial herbaceous leguminous plant, which comes from the dried rhizome of the leguminous plant Astragalus membranaceus or Astragalus mongolica. It is sweet in nature, slightly warm in taste, and enters the spleen and lung meridians. Astragalus has the effects of invigorating qi and strengthening the exterior, promoting diuresis and reducing swelling, promoting fluid and nourishing blood, relieving stagnation and relieving arthritis, expelling toxins and draining pus, and healing sores and promoting tissue regeneration. Astragalus mainly contains active ingredients such as polysaccharides, saponins, and flavonoids. Its pharmacological research mainly focuses on immunomodulation, anti-tumor, anti-virus, anti-aging, and treatment of diabetes and its complications.

[0036] Codonopsis mainly comes from the dried roots of Codonopsis pilosula, Codonopsis pilosula, Codonopsis pilosula, Codonopsis pilosula, Codonopsis pilosula, Codonopsis pilosula, Codonopsis pilosula. It is mild in nature and sweet in taste. It has the effects of tonifying the middle qi and replenishing qi, and promoting the production of body fluid. It is mainly used for spleen and stomach weakness, deficiency of qi and blood, fatigue, lack of appetite, thirst, chronic diarrhea, and prolapse of the anus. Its pharmacological effects are mainly focused on regulating immune function, anti-inflammatory effects, effects on cardiovascular function, effects on gastrointestinal function, anti-tumor effects, anti-aging effects, effects on memory and learning ability, and antioxidant effects.

[0037] The invention uses astaxanthin in combination with astragalus extract, codonopsis extract, deer glue peptide and albumin peptide to obtain a composition capable of significantly inhibiting the activity of cyclooxygenase-2.

[0038] In a specific embodiment of the present invention, the composition comprises the following components by weight: 35-45 parts of astaxanthin, 5-7 parts of astragalus extract, 5-7 parts of codonopsis extract, 4-6 parts of deer glue peptide and 4-6 parts of albumin peptide.

[0039] In a specific embodiment of the present invention, astaxanthin is derived from Haematococcus pluvialis. Further, the astaxanthin is astaxanthin microcapsule powder.

[0040] Studies have found that different species have different contents of astaxanthin and astaxanthin esters, significant differences in the composition of optical isomers, and significant differences in biological activity. The present invention uses astaxanthin from Haematococcus pluvialis, combined with Astragalus extract, Codonopsis pilosula extract, deer glue peptide and albumin peptide, which can significantly inhibit the activity of COX-2. Haematococcus pluvialis contains free astaxanthin and esterified astaxanthin.

[0041] In a specific embodiment of the present invention, the total nitrogen of deer glue peptide is ≥15wt%.

[0042] In a specific embodiment of the present invention, in the albumin peptide, the protein content is ≥75wt%, and the oligopeptide content is ≥60wt%.

[0043] In a specific embodiment of the present invention, the astragalus extract is a water extract of astragalus, and the codonopsis extract is a water extract of codonopsis.

[0044] In a specific embodiment of the present invention, in the composition, the protein content is ≥1.82wt%, the fat content is ≥0.2wt%, and the carbohydrate content is ≥24.5wt%.

[0045] For example, in different embodiments, in the composition, the protein content can be 1.82wt%, 2wt%, 5wt%, 8wt%, 10wt%, 12wt%, 15wt%, 17.1wt% or a range consisting of any two thereof; the fat content can be 0.2wt%, 0.3wt%, 0.4wt%, 0.5wt% or a range consisting of any two thereof; the carbohydrate content can be 24.5wt%, 30wt%, 35wt%, 40wt%, 45wt%, 50wt%, 55wt%, 56.7wt% or a range consisting of any two thereof.

[0046] In a specific embodiment of the present invention, the composition comprises at least one of powder, granules, tablets, capsules and oral liquid.

[0047] In actual operation, in order to improve the storage convenience, stability and compliance of the composition, the composition can be made into different dosage forms according to actual needs. According to different dosage form requirements, different proportions and different types of auxiliary materials are added to the active ingredients (astaxanthin, astragalus extract, codonopsis extract, deer glue peptide and albumin peptide), and prepared by corresponding methods. For example, sorbitol, magnesium stearate, silicon dioxide, etc. can be added to the tablets for tableting.

[0048] Among them, excipients include but are not limited to: binders (such as microcrystalline cellulose, alginate, gelatin and polyvinyl pyrrolidone), fillers (such as starch, sucrose, glucose and anhydrous lactic acid), disintegrants (such as cross-linked PVP, cross-linked sodium carboxymethyl starch, cross-linked sodium carboxymethyl cellulose, and low-substituted hydroxypropyl cellulose), lubricants (magnesium stearate, aluminum stearate, talc, polyethylene glycol, sodium benzoate), wetting agents (such as glycerol), surfactants (such as cetyl alcohol) and absorption enhancers, flavoring agents, sweeteners, diluents, coating agents, etc.

[0049] Another aspect of the present invention provides a method for preparing any one of the above-mentioned compositions, comprising the following steps: mixing the components in proportion.

[0050] If a corresponding dosage form is to be prepared, the active component and the corresponding excipients are compounded in proportion and prepared according to the conventional preparation method of the corresponding dosage form.

[0051] Another aspect of the present invention provides use of any one of the above-mentioned compositions in the preparation of a preparation for inhibiting cyclooxygenase-2 activity.

[0052] The present invention also provides the use of any one of the above compositions in preparing a preparation for inhibiting IL-6. Specifically, the use of the composition in preparing a preparation for inhibiting the production of IL-6 in PAW264.7 cells induced by LPS.

[0053] In a specific embodiment of the present invention, the preparation includes at least one of food, health care product and medicine.

[0054] Example 1

[0055] This example provides a composition for inhibiting cyclooxygenase-2 activity, comprising the following components by weight: 40 parts of astaxanthin microcapsule powder, 6 parts of astragalus extract, 6 parts of codonopsis extract, 5 parts of deer glue peptide and 5 parts of albumin peptide.

[0056] Among them, astaxanthin microcapsule powder is derived from Haematococcus pluvialis and is commonly available in the market;

[0057] Astragalus extract is the water extract of Astragalus, and Codonopsis extract is the water extract of Codonopsis, and both suppliers are Xi'an Tianyi Biotechnology Co., Ltd.;

[0058] The total nitrogen of deer glue peptide is 15wt%, and the supplier is Wuhan Tiantianhao Biological Products Co., Ltd.;

[0059] The protein content of albumin peptide is 75wt%, and the oligopeptide content is 60wt%. The supplier is Wuhan Tiantianhao Biological Products Co., Ltd.

[0060] The preparation method of the composition for inhibiting cyclooxygenase-2 activity of this embodiment comprises the following steps:

[0061] Mix astaxanthin microcapsule powder, astragalus extract, codonopsis extract, deer glue peptide and albumin peptide evenly according to proportion.

[0062] Embodiments 2 to 10

[0063] Examples 2 to 10 refer to the preparation methods of the composition for inhibiting cyclooxygenase-2 activity provided in Example 1, except that the dosage of each component is different.

[0064] The dosage information of each component in Examples 2 to 10 is shown in Table 1.

[0065] Table 1 Amount information of each component of Examples 2 to 10 (parts by weight)

[0066] serial number Astaxanthin Microcapsule Powder Astragalus Extract Codonopsis Extract Deer glue peptide Albumin peptide Example 2 20 3 3 1 1 Example 3 30 3 3 1 1 Example 4 40 3 3 1 1 Example 5 50 3 3 1 1 Example 6 40 6 6 1 1 Example 7 40 6 6 10 10 Example 8 40 10 10 1 1 Example 9 40 10 10 5 5 Example 10 40 10 10 10 10

[0067] Comparative Example 1

[0068] Same as the astaxanthin microcapsule powder in Example 1.

[0069] Comparative Example 2

[0070] The astragalus extract and the codonopsis extract were mixed at a mass ratio of 1:1. The astragalus extract and the codonopsis extract were the same as those in Example 1.

[0071] Experimental Example 1

[0072] The physical and chemical properties of the compositions prepared in different embodiments were characterized, and the test results are shown in Table 2.

[0073] Table 2 Physical and chemical properties test results of different compositions

[0074] serial number Protein (wt%) Fat (wt%) Carbohydrate (wt%) Example 1 8.61 0.4 48.8 Example 2 1.83 0.2 24.5 Example 3 1.82 0.3 34.2 Example 4 1.82 0.4 44.1 Example 5 1.84 0.5 54.6 Example 6 2.01 0.4 48.2 Example 7 16.86 0.4 48.9 Example 8 2.25 0.4 54.6 Example 9 8.85 0.4 55.9 Example 10 17.1 0.4 56.7

[0075] Experimental Example 2

[0076] COX-2 activity inhibition experiment

[0077] Reagents: LPS, Sigma-Aldrich, USA; DMEM culture medium, PBS buffer, double antibody, Gibco, USA; FBS, Wuhan Donglimu Biotechnology Co., Ltd.; CCK-8 detection kit, DMSO, Shanghai Biyuntian Biotechnology Co., Ltd.; IL-6 detection kit, cyclooxygenase-2 (COX-2) ELISA kit, Quanzhou Ruixin Biotechnology Co., Ltd.

[0078] Cells: Mouse RAW264.7 mononuclear macrophages, Wuhan Pronocell Life Science Co., Ltd.;

[0079] Experimental instruments: carbon dioxide cell culture box, inverted microscope, ultra-low temperature refrigerator, centrifuge, microplate reader, clean bench, ordinary refrigerator, pipette;

[0080] Test substances: Test substance 1 is the composition product prepared according to Example 1; Test substance 2 is the product of Comparative Example 1; Test substance 3 is the product of Comparative Example 2; during the experiment, the concentration of test substance 1 was 620 mg / L, test substance 2 was the astaxanthin microcapsule powder contained in the same dose as test substance 1, and test substance 3 was the astragalus extract and codonopsis extract contained in the same dose as test substance 1.

[0081] Experimental methods:

[0082] 1.1 Cell culture

[0083] Preparation of complete culture medium: Add 10% calf serum and 1% double antibody to serum-free high-glucose DMEM culture medium, store at 4 degrees Celsius, and use within one week.

[0084] 1.2 Cell culture and passage: Take RAW264.7 cells, add DMEM medium containing 10% FBS and 1% double antibody, and culture at 5% CO2 and 37°C. Replace the culture medium every 1-2 days, and take cells in the logarithmic growth phase for subsequent experiments.

[0085] CCK-8 cytotoxicity assay

[0086] Take RAW264.7 cells in the logarithmic growth phase and adjust the cell density to 5×104 / mL, cultured for 24h. Test group 1, test group 2 and test group 3 were set up, with 6 wells in each group, and the test substances were added and cultured for 24h. CCK-8 kit was used to detect the survival rate of RAW264.7 cells.

[0087] Effects on IL-6 and COX-2 levels in LPS-induced macrophage inflammation model

[0088] Take RAW264.7 cells in the logarithmic growth phase and adjust the cell density to 5×10 6 / mL, inoculated in a 10cm culture dish, cultured at 37℃, 5% CO2 for 24h, added LPS to a final concentration of 1μg / mL, and continued to culture for 6h. Add test substance 1, test substance 2 and test substance 3 respectively, and cultured at 37℃, 5% CO2 for 24h. Determine IL-6 and COX-2 levels according to the kit instructions.

[0089] Figure 1 The effects of the composition prepared in Example 1 of the present invention (test substance 1) and comparative example 1 (test substance 2) and comparative example 2 (test substance 3) on the proliferation of RAW264.7 cells are shown in Table 1. Figure 1 It can be seen that the cell survival rates of test substance 1, test substance 2 and test substance 3 are all above 90%, indicating that test substance 1, test substance 2 and test substance 3 have no effect on the viability of RAW264.7 cells, that is, they have no cytotoxicity.

[0090] Figure 2 The effects of the composition prepared in Example 1 of the present invention (test substance 1) and comparative example 1 (test substance 2) and comparative example 2 (test substance 3) on IL-6 levels are shown in Table 1. Figure 2 It can be seen that the IL-6 level in the model group was significantly higher than that in the blank group, and the difference was extremely significant (p<0.01), indicating that the LPS-induced macrophage inflammation model was successfully established. Test 1 and test 2 had the activity of reducing IL-6 levels, but only test 1 was different from the model group, and the difference was extremely significant (p<0.01). The IL-6 level activity in the test 3 group was significantly higher than that in the test 1 group, and compared with the model group, the reduction range and trend were not obvious.

[0091] Figure 3 The effects of the composition prepared in Example 1 of the present invention (test substance 1) and comparative example 1 (test substance 2) and comparative example 2 (test substance 3) on COX-2 levels are as follows: Figure 3 It can be seen that the COX-2 level in the model group was higher than that in the blank group, and the difference was extremely significant (p<0.01). The COX-2 levels in the test substance 1 and test substance 2 groups were lower than those in the model group, which were extremely significant (p<0.01) and significant (p<0.05) compared with the model group, respectively. The COX-2 level in the test substance 3 group was significantly higher than that in the test substance 1 group, and there was no significant difference between the test substance 3 group and the model group.

[0092] From the above results, it can be seen that test substance 1 has the effect of reducing the activity levels of IL-6 and COX-2 in the LPS-induced macrophage inflammation model, and the effect is better than test substance 2 and test substance 3. That is, the effect of test substance 1 in reducing the activity levels of IL-6 and COX-2 is significantly better than the same dose of pure astaxanthin microcapsule powder and the same dose of a mixture of pure astragalus extract and Codonopsis pilosula extract.

[0093] Finally, it should be noted that the above embodiments are only used to illustrate the technical solutions of the present invention, rather than to limit it. Although the present invention has been described in detail with reference to the aforementioned embodiments, those skilled in the art should understand that they can still modify the technical solutions described in the aforementioned embodiments, or replace some or all of the technical features therein with equivalents. However, these modifications or replacements do not cause the essence of the corresponding technical solutions to deviate from the scope of the technical solutions of the embodiments of the present invention.

Claims

1. A composition, characterized in that It includes the following components by weight: 20-50 parts of astaxanthin, 3-10 parts of astragalus extract, 3-10 parts of codonopsis extract, 1-10 parts of deer glue peptide and 1-10 parts of albumin peptide.

2. The composition according to claim 1, characterized in that The invention comprises the following components by weight: 35-45 parts of astaxanthin, 5-7 parts of astragalus extract, 5-7 parts of codonopsis extract, 4-6 parts of deer glue peptide and 4-6 parts of albumin peptide.

3. The composition according to claim 1, characterized in that The astaxanthin is derived from Haematococcus pluvialis; Preferably, the astaxanthin is astaxanthin microcapsule powder.

4. The composition according to claim 1, characterized in that The total nitrogen content of the deer glue peptide is ≥15wt%.

5. The composition according to claim 1, characterized in that In the albumin peptide, the protein content is ≥75wt%, and the oligopeptide content is ≥60wt%.

6. The composition according to claim 1, characterized in that The astragalus extract is a water extract of astragalus, and the codonopsis extract is a water extract of codonopsis.

7. The composition according to claim 1, characterized in that In the composition, the protein content is ≥1.82wt%, the fat content is ≥0.2wt%, and the carbohydrate content is ≥24.5wt%.

8. The composition according to claim 1, characterized in that The composition comprises at least one of powder, granules, tablets, capsules and oral liquid; Preferably, the composition further comprises auxiliary materials.

9. Use of the composition according to any one of claims 1 to 8 in the preparation of a preparation for inhibiting cyclooxygenase-2 activity.

10. The use according to claim 9 is characterized in that: The preparation comprises at least one of food, health care product and medicine.

Images